A bullet pierced her lung.
一颗子弹洞穿她的肺。
The kid has a good pair of
lungs.
这个小孩子哭声洪亮。
Tom was taken to the hospital with broken ribs and a punctured lung.
汤姆肋骨骨折、肺部穿孔，被送往医院。
The
lungs are the primary organs responsible for respiration in humans.
肺是人体进行呼吸的主要器官。
Smoking severely damages lung function, increasing the risk of chronic obstructive pulmonary disease (COPD) and cancer.
吸烟严重损害肺功能，增加慢性阻塞性肺病（COPD）和肺癌的风险。
Lung capacity is an important indicator of overall physical fitness.
肺活量是衡量整体身体状况的重要指标。
She underwent surgery to remove her damaged lung due to tuberculosis.
她因肺结核接受了切除损坏肺部的手术。
After exercising, she felt a tightness in her chest – a sign of lactic acid buildup in her
lungs.
运动后，她感到胸闷，这是乳酸在肺部积聚的迹象。
Breathing exercises can help improve lung elasticity and strengthen respiratory muscles.
呼吸练习有助于提高肺部弹性并增强呼吸肌。
The doctor recommended she use an inhaler to dilate her constricted lung passages.
医生建议她使用扩张器来舒张收缩的气道。
Healing from a lung infection can take weeks or even months, depending on the severity.
从肺部感染中恢复可能需要数周甚至数月，取决于病情的严重程度。
The patient's
lungs were clear after the X-ray, indicating a healthy respiratory system."
X光显示患者的肺部清晰，表明呼吸道健康。
Lung transplants are a life-saving procedure for those with end-stage lung diseases.
对于患有终末期肺病的人来说，肺移植是一种挽救生命的手术。
Following the approval of a new indication, Toripalimab, China's first homegrown PD-1 anti-cancer treatment, has become the first approved perioperative therapy for lung cancer in China and the second worldwide, its developer Shanghai Junshi Biosciences Co Ltd said.
开发商上海君实生物科技有限公司表示，在新适应症获得批准后，中国首个国产PD-1抗癌治疗药物托里帕利单抗已成为中国首个获得批准的癌症围手术期治疗方法，也是全球第二个获得批准。
The supplemental new drug application for the drug in combination with chemotherapy as perioperative treatment and subsequently, monotherapy as adjuvant therapy for the treatment of adult patients with resectable stage IIIA-IIIB non-small cell lung cancer (NSCLC) has been approved by the National Medical Products Administration, the company announced Tuesday.
该公司周二宣布，国家医疗产品管理局已批准该药物与化疗联合作为围手术期治疗的补充新药申请，以及随后作为辅助治疗的单药治疗，用于治疗可切除的IIIA-IIIB期癌症（NSCLC）成年患者。
Lung cancer is currently the world's second most prevalent malignant tumor, with the highest mortality rate.
癌症是目前世界第二大恶性肿瘤，死亡率最高。
According to the World Health Organization, in 2020, the number of new lung cancer cases in China amounted to 816,000, accounting for 17.9 percent of all new cancer cases in China.
根据世界卫生组织的数据，2020年，中国癌症新增病例达81.6万例，占中国癌症新增病例的17.9%。
In the same year, the number of lung cancer deaths in China amounted to 715,000, accounting for 23.8 percent of all cancer deaths in China.
同年，中国癌症死亡人数达71.5万人，占中国癌症死亡人数的23.8%。
Among lung cancer, NSCLC is a major subtype, accounting for approximately 85 percent of all cases.
在癌症中，NSCLC是一种主要的亚型，约占所有病例的85%。
German biopharmaceutical company Boehringer Ingelheim's China arm has inked a strategic cooperation agreement with Chinese high-tech company ChromX Health, to jointly push forward research on interstitial lung diseases and search for innovative early diagnosis and intervention solutions.
德国生物制药公司勃林格殷格翰的中国分公司与中国高科技公司ChromX Health签署了战略合作协议，共同推进间质性肺病的研究，并寻求创新的早期诊断和干预解决方案。
Interstitial lung diseases, or ILD, are a large group of disorders that can cause progressive scarring of lung tissue if not treated timely and effectively, resulting in difficulty to breathe and even death.
间质性肺病（ILD）是一大类疾病，如果不及时有效治疗，会导致肺组织进行性瘢痕形成，导致呼吸困难甚至死亡。
During the CIIE, Boehringer Ingelheim also exhibited a new drug candidate at the Phase-3 clinical trial for treating idiopathic pulmonary fibrosis, a rare and chronic lung disease.
在CIIE期间，勃林格殷格翰还在治疗特发性肺纤维化（一种罕见的慢性肺病）的3期临床试验中展示了一种新的候选药物。
"R&D efforts will address not only the cancers prevalent in Asia but those that are prevalent globally, such as breast, lung, prostate and colorectal cancers," she said.
她说：“研发工作不仅将解决亚洲流行的癌症，还将解决全球流行的癌症问题，如乳腺癌、肺癌、前列腺癌和结直肠癌。”。
The drug achieved approval in China in 2021 and AstraZeneca is developing its global approvals for both lung and gastric cancer drugs.
该药物于2021年在中国获得批准，阿斯利康正在开发其肺癌和胃癌药物的全球批准。
COPD, an inflammatory lung disease that causes obstructed airflow in the lungs, is even more widespread－close to 100 million of the country's adult population suffer from this chronic pulmonary disease, which has become the third leading cause of death in China.
慢性阻塞性肺病是一种导致肺部气流受阻的炎症性肺病，其传播范围更广——中国近1亿成年人口患有这种慢性肺病，已成为中国第三大死亡原因。
"So far, the drug has covered major cancer types, including lymphoma, lung cancer, liver cancer, esophageal cancer and gastric cancer, benefiting millions of Chinese patients," he said.
他说：“到目前为止，该药物已涵盖主要的癌症类型，包括淋巴瘤、癌症、癌症、食管癌症和癌症，使数百万中国患者受益。”。
Data from the World Health Organization showed that every 20 seconds, a person in the world dies from diseases triggered from air pollution, such as pneumonia, lung cancer and chronic respiratory disorders.
世界卫生组织的数据显示，世界上每20秒就有一人死于空气污染引发的疾病，如肺炎、癌症和慢性呼吸系统疾病。
It has published performance data of early screening with the HIFI system for liver cancer and multiple tumor types that include lung, gastric, colorectal, esophageal and pancreatic cancer.
它已经发表了HIFI系统对癌症和多种肿瘤类型（包括肺癌、胃癌、结直肠癌、食管癌和癌症）进行早期筛查的性能数据。
Biopharmaceutical companyxa0Pfizer announced on Friday that Lorbrena, the world's first third-generation anaplastic lymphoma kinase inhibitor, has been approved by China's National Medical Products Administration for the treatment of patients with ALK-positive locally advanced or metastatic non-small cell lung cancer.
生物制药公司xa0Pfizer周五宣布，世界上第一种第三代间变性淋巴瘤激酶抑制剂Lorbrena已被中国国家药品监督管理局批准用于治疗ALK阳性的局部晚期或转移性癌症患者。
As Pfizer's innovative targeted lung cancer therapy, the tablet demonstrates breakthrough in improving patients' progression-free survival, can better penetrate blood-brain barrier, and have less drug resistance, said the company.
辉瑞公司表示，作为其创新的靶向性癌症治疗方案，该片在提高患者无进展生存率方面取得了突破，可以更好地穿透血脑屏障，并减少耐药性。
Lung cancer has the highest incidence and mortality rates among all malignant tumors in China.
在中国所有恶性肿瘤中，癌症的发病率和死亡率最高。
Japanese pharmaceutical company Takeda announced on Friday that Brigatinib, an innovative lung cancer drug, has been approved by China's National Medical Products Administration, bringing a new treatment option for lung cancer patients.
日本武田制药公司周五宣布，癌症创新药物Brigatinib已获得中国国家药品监督管理局的批准，为癌症患者带来了一种新的治疗选择。
The tablet is a new anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor used to treat those suffering from non-small cell lung cancer.
该片是一种新型间变性淋巴瘤激酶（ALK）酪氨酸激酶抑制剂，用于治疗癌症患者。
It has been listed as a first-line preferred drug in national clinical practice guidelines of cancer and the guidelines for the diagnosis and treatment of non-small cell lung cancer.
已被列为癌症国家临床实践指南和癌症非小细胞肺癌诊治指南的一线首选药物。
The approval of the medicine also marked Takeda China's official entrance in the field of lung cancer treatment, the company said.
该公司表示，该药物的批准也标志着武田中国正式进入癌症治疗领域。
Lu Shun, one of the country's leading experts in lung cancer and director of the department of oncology at the Shanghai Chest Hospital Affiliated with Shanghai Jiao Tong University, said there have been therapies in this disease area but their control of metastasis in the brain is insufficient and there exists an unmet clinical need.
癌症专家、上海交通大学附属上海胸科医院肿瘤科主任陆顺说，在这一疾病领域已经有了治疗方法，但他们对脑转移的控制不足，临床需求尚未得到满足。
These patients include the elderly and people with chronic kidney or lung issues, cardiovascular disease, diabetes and other high-risk factors.
这些患者包括老年人和患有慢性肾脏或肺部问题、心血管疾病、糖尿病和其他高危因素的人。
The partnership with the local diagnostic company will further empower full-cycle patient management in various ways, including fast reimbursement to optimize the diagnosis of Janssen's target therapeutic areas such as lung cancer and urothelial cancer.
与当地诊断公司的合作将以各种方式进一步增强全周期患者管理能力，包括快速报销，以优化杨森目标治疗领域的诊断，如肺癌癌症和尿路上皮癌症。
Key exhibits include innovative cancer therapies such as the PD-1 inhibitor that is used to treat drug-resistant lung cancer patients.
关键展品包括创新的癌症疗法，如用于治疗耐药肺癌癌症患者的PD-1抑制剂。
For instance, the new drug application of an oral innovative drug for lung cancer was given a priority review designation, leading to simultaneous submissions to National Drug Authority in China and globally.
例如，一种针对肺癌的新型口服药物获得了优先审查资格，从而实现了在中国和全球范围内的国家药品管理局同步提交申请。
Guoyuan Securities predicted China's early testing market for lung cancer will hit 10.65 billion yuan in 2030, and early screening market for colorectal cancer will reach 9.6 billion yuan.
国元证券预测，2030年中国肺癌早检市场将达到106.5亿元，而结直肠癌早筛市场将达96亿元。
Besides doctor training, GE Healthcare will cooperate with other medical institutions and provide complimentary screenings of electrocardiograms and for breast and lung cancer for high-risk groups who live in remote areas.
除了医生培训之外，GE医疗保健还将与其他医疗机构合作，为居住在偏远地区的高危人群提供免费的心电图检查以及乳腺癌和肺癌筛查。
The patient recruiting platform has helped more than 10 leading pharmaceutical companies, such as Chia Tai Tianqing Pharmaceutical Group and Innovent, to recruit subjects for more than 60 new drug clinical trial projects in areas such as lung cancer, liver cancer, gynecological tumors and gastrointestinal tumors.
该患者招募平台已经帮助包括郑州智同天清制药集团和信达生物在内的10多家领先的制药公司，在肺癌、肝癌、妇科肿瘤和胃肠肿瘤等领域，为超过60个新药临床试验项目招募受试者。
Opdivo has since been approved for use in the treatment of lung cancer, head and neck cancer, and gastric cancer in China.
Opdivo自那以后已被批准在中国用于治疗肺癌，头颈癌，以及胃癌。但更准确的翻译应该是：
The first phase of the partnership will focus on liver and lung cancer, Genetron Health said in a press release.
Genetron Health在一份新闻稿中表示，该合作的第一阶段将专注于肝癌和肺癌。
Meanwhile, JD Health’s online network of doctors and retail pharmacies will have an option to use Genetron Health’s products to help non-small cell lung cancer patients make their therapy selection decisions.
与此同时，京东健康旗下的在线医生网络和零售药店将能够使用Genetron Health的产品，帮助非小细胞肺癌患者做出治疗选择决策。
United States-based Eli Lilly and Innovent, a domestic pharmaceutical company, jointly announced on Sunday the China market launch of a PD-1 inhibitor to be used for the indication of a main type of non-small cell lung cancer, a major tumor species threatening people's health in China and worldwide.
美国药企礼来公司和国内药企信达生物周日联合宣布，一款用于治疗主要类型的非小细胞肺癌的PD-1抑制剂在中国上市。非小细胞肺癌是威胁中国乃至全球人们健康的主要肿瘤类型之一。
Lung cancer is the No 1 malignant tumor regarding both incidence and mortality rates in China.
肺癌是中国发病率和死亡率均为第一的恶性肿瘤。
Nearly one in four cancer patients died of lung cancer in 2020, according to the International Agency for Research on Cancer.
根据国际癌症研究机构的数据，2020年，近四分之一的癌症患者死于肺癌。
Nearly 85 percent of lung cancer patients are categorized as sufferers of non-small cell lung cancer, according to experts.
据专家称，近85%的肺癌患者被归类为非小细胞肺癌患者。
"Market launch of the drug provided an opportunity for terminal-stage lung cancer patients to have a first-line therapy, a better option than existing chemotherapy," Zhang said.
张说：“这款药物的上市，让末期肺癌患者拥有了第一线治疗方案，比现有的化疗方案更具优势。”
The company said the technology-empowered products will be available for lung and other cancers in a few years to help the company take an early grip of the billion-dollar early tumor detection market in China.
该公司表示，这款以技术为驱动的产品将在未来几年内应用于肺癌和其他癌症，旨在帮助公司在价值数十亿美元的中国早期肿瘤检测市场抢占先机。
Broncus Holding Corp, a global leader in diagnostic and therapeutic technology for lung diseases, announced on Thursday that it has raised tens of million dollars in its Series D round of fundraising led by FountainVest Partners.
全球肺部疾病诊断和治疗技术的领头羊Broncus Holding Corp于周四宣布，它在由FountainVest Partners牵头的D轮融资中筹集了数千万美元的资金。
The new financing will be used for the commercialization and development of technology across lung cancer, emphysema and other important lung diseases.
这笔新的融资将用于肺癌、肺气肿以及其他重要肺部疾病的科技商业化和开发。
Broncus mainly develops diagnostic and therapeutic technology for lung diseases with focus on the diagnosis of lung cancer and the treatment of emphysema.
Broncus 主要致力于开发针对肺部疾病的诊断和治疗技术，专注于肺癌的诊断以及肺气肿的治疗。
Its bronchoscopic trans-parenchymal nodule access technology, for instance, is able to access any part of the entire lung, reaching directly the lesions that are not connected to or adjacent to an airway.
它的支气管镜下跨肺实质结节访问技术能够到达肺部的任何部位，直接接触到未与气道相连或相邻的病灶。这项技术使得对肺部深处的病变进行诊断和治疗成为可能。
"Our breakthrough navigation technology is enabling us to accelerate the development and commercialization of precise interventional technologies for diagnosis and treatment in order to improve options for patients with lung diseases and the physicians that care for them," said Broncus CEO Zhan GuoweiFountainVest's Managing Director Jason Li said, "FountainVest Partners is excited to be supporting Broncus, one of the leading global players in the field of interventional diagnosis and therapy of lung diseases with proven capabilities to develop cutting edge innovative medical technologies.
“我们的突破性导航技术使我们能够加速开发和商业化精确的介入技术，用于肺部疾病的诊断和治疗，从而为患者和照顾他们的医生提供更好的选择，”Broncus首席执行官Zhan Guowei说。
Medical experts explained that neuroendocrine tumors can happen to multiple organs, including the stomach, intestine, pancreas, and lung, and its incidence rate has been rising over past years in the country.
医学专家指出，神经内分泌肿瘤可以发生在包括胃、肠、胰腺和肺在内的多个器官，近年来这类肿瘤的发病率在我国呈上升趋势。
Biotech company BeiGene Ltd announced Thursday its anti-PD-1 antibody tislelizumab has received approval from the country's National Medical Products Administration for use in combination with two chemotherapy regimens as a first-line treatment for patients with advanced squamous non-small cell lung cancer.
生物科技公司 BeiGene Ltd 周四宣布，其抗 PD-1 抗体替雷利珠单抗已获得中国国家药品监督管理局的批准，可用于与两种化疗方案联合使用，作为晚期鳞状非小细胞肺癌患者的一线治疗。
That marked the third approval in China for tislelizumab, and its first in a lung cancer indication.
这是替雷利珠单抗在中国获得的第三次批准，也是其在肺癌适应症上的首次获批。
"This approval for tislelizumab is an important milestone for BeiGene, for tislelizumab, and for patients and healthcare practitioners in China fighting advanced squamous non-small cell lung cancer," said Wu Xiaobin, president of the company and general manager of its China arm.
“泰斯乐利珠单抗的这一批准对 BeiGene、泰斯乐利珠单抗以及中国对抗晚期鳞状非小细胞肺癌的患者和医疗保健专业人员来说，都是一个重要里程碑，”该公司总裁兼中国区总经理吴晓滨表示。
"This is our sixth global approval for an internally developed product, and our first approval for tislelizumab in a lung cancer indication, an area where we believe tislelizumab can have a large impact for patients.
这是我们的第六个全球批准的内部开发产品，也是替雷利珠单抗在肺癌适应症上的首次获批，我们相信替雷利珠单抗在这个领域可以为患者带来重大影响。
""Lung cancer is the leading cause of cancer-related death in China, and with non-small cell lung cancer comprising the most common form of the disease, there is significant patient need," said Wang Jie, an oncologist with the National Cancer Center/Cancer Hospital under the Chinese Academy of Medical Sciences & Peking Union Medical College.
“肺癌是中国癌症死亡的主要原因，其中非小细胞肺癌是最常见的类型，因此患者的需求非常大，”中国医学科学院肿瘤医院/国家癌症中心的肿瘤科医生王杰表示。
Li Ning, chief executive officer of Junshi Biosciences, said the company found great unmet medical needs exist in other countries where patients are endangered by this deadly disease, although it prioritizes cancer types with high prevalence in China such as nasopharyngeal carcinoma, lung and liver cancer.
In traditional Chinese medicine, houtougu, or hericium erinaceus, helps digestion by benefiting the five internal organs — heart, liver, spleen, lungs and kidneys.
It has launched home screening products targeting bowel, cervical, gastric and lung cancers.
The AI Cloud solution which leverages the Huawei Cloud that was built in South Africa allows for fast, highly accurate diagnosis of coronavirus pneumonia by analyzing CT scans of a patients' lungs.
Wang Peijun, chairman of the committee of the radiology branch under the Shanghai Medical Association, said even though computerized tomography imaging offers valuable guidance for COVID-19 detection, the nucleic acid test is still a gold standard for confirmed cases, as CT image shadows could be caused by other lung diseases.
Its CT lung module algorithm software, in cooperation with the server of the nation's tech giant Huawei Technologies Co, hit a high accuracy rate at 96 percent, the highest in the competition.
A supporting tumor gene detection kit for the system has also been successfully developed, which can be adapted to many types of samples from tissues to body fluids, including glioma, lung, urothelial, breast and thyroid cancers, covering the fields of early screening, molecular pathology diagnosis and medication guidance, the company said.
Another key area will be autoimmune diseases and inflammation, especially ulcerative colitis, Crohn's disease, chronic lung obstruction and severe asthma, and we hope to discover new targets and research directions.
The deeper job cuts suggest the negative publicity surrounding lung injury cases has hit sales harder than anticipated, or the company expects sales to decline sharply.
The US Centers for Disease Control and Prevention (CDC) said 2,051 cases of lung injury have been reported in 49 states and the District of Columbia through Nov 5.
Health officials have not identified the cause of the lung injuries, but the only common thread is that patients reported the use of e-cigarettes.
Investigators believe vitamin E acetate, an oil used as a thickening agent in food, dietary supplements, skin creams and present in some vaping products, may be the cause of the of the lung damage.
MapKure plans to develop a new drug called BGB-3245 that could help inhibit certain forms of mutations that have been identified in some solid tumors as drivers of their cancerous growth, such as non-small cell lung cancer, colorectal cancer, thyroid cancer, and brain tumors, according to BeiGene's statement on Tuesday.
It will also meet medical AI needs in heart, brain, lung, breast and prostate diseases.
com's system has mainly been used in medical imaging to screen for lung cancer, breast cancer, cerebral hemorrhages and cerebral infarctions.
Lung cancer and breast cancer are among the top killers for men and women, respectively," Qiao said.
One of the products launched is an intelligent 4D imaging system for chest CT, which is the world's first AI system that can deliver imaging-based diagnosis for all the type of lesions in lung.
China's medical AI has developed rapidly over a short period of time, but many can only detect pulmonary nodules — small rounds or growths in lung, according to Jin Zhengyu, chairman of Chinese Society of Radiology.
That provides little assistance to radiologists in clinical practice, because pulmonary nodules only account for about 50 percent of lung lesions in a chest CT, Jin said.
In China, cancers with high morbidity and mortality, such as lung cancer and breast cancer, have also become urgent public health concerns.
With over nine decades of expertise in mice genetics, Jackson Laboratory has offered China over 11,000 strains of mice that can be applied toward researching many diseases, such as lung cancer and diabetes.
Novartis Group China, an affiliate of the Swiss healthcare giant, is displaying its groundbreaking medicines and technologies at CIIE, including a number of innovative medicines for heart failure, respiratory disease, blood diseases, lung cancer, kidney cancer and breast cancer.
According to Zhao, Opdivo, the soon-to-be-launched immuno-oncology non-smallcell lung cancer, or NSCLC, treatment product, will become a strategic move for the company to rejig both its product line and business model in the Chinese market.
According to a report published in China Cancer, a journal focused on the prevention and treatment of cancer in China, the battle against lung cancer has always been the most challenging one due to the disease's top morbidity and mortality rate among all kinds of cancer.
In China, 781,000 people are diagnosed with lung cancer each year, and the number will rise to 800,000 in 2020, the report said.
According to World Health Organization data, 1.7 million people die because of lung cancer each year.
As the most common type of lung cancer, NSCLC has accounted for about 85 percent of all lung cancers, with the five-year survival rate being less than 5 percent in the end-stage period, the report said.
Apart from the treatment of lung cancer, BMS is also exploring immuno-oncology treatments of liver cancer, stomach cancer, esophagus cancer and other high-incidence cancer, Zhao said.
Their aim is to develop the blockchain electronic medical case system to tackle lung cancer and liver diseases.
It also has worked with the local government to establish its first JLABS, an open incubator for innovative technologies, outside North America and Europe in the city, with its first project initiated last week focusing on treatment of lung cancer, a disease affecting many Chinese.
To embrace the trend, the company has scrambled to develop AI-enabled products to help doctors read medical images to speed up diagnosis and prevent misdiagnosis in diseases including lung, uterine, neck and breast cancers.
For example, lung cancer, liver disease, upper GI and throat cancer.
J&J is planning its first global lung cancer R&D center in China.
Unfortunately, about 60 percent of the world's cases of lung cancer are here in China.
It is an opportunity to bring our pharmaceutical scientists, medical device scientists, and even our consumer behavior scientists together to see how could we discourage people from smoking in the first place, detect cancer earlier in the metastatic process, and bring about more holistic approaches combining therapeutic and surgical intervention at the right time and place to ultimately find a way to care for lung cancer comprehensively.
These surgical products will be used to treat critical diseases such as lung cancer, liver cancer and gastric cancer.
While air pollution is bad for everyone, it's particularly harmful to young children whose immune system and lungs are not fully developed.
Part of the Johnson & Johnson group, Janssen will focus on developing medicines, including drugs to fight lung disease, which is a major problem in the country.
To combat lung cancer, Johnson & Johnson aim to set up a global research and development center in the country.
Through innovative methods, the center hopes to lower the cases of lung cancer and increase survival rates among those affected by the disease.
They will jointly develop and market testing kits for patients with thyroid cancer and lung cancer who have mutation in the RET gene for accurate diagnosis and treatment.
Besides, the company's first AI-discovered drug candidate, for the treatment of a rare and chronic lung disease called idiopathic pulmonary fibrosis, has finished dosing subjects for a phase-1 clinical study in China.
For instance, the company showcased during the inaugural CIIE an innovative medicine for treating a specific lung cancer.
People with the disorder produce either no or insufficient hemoglobin, the protein molecule in red blood cells that carries oxygen from the lungs to the body's tissues and returns carbon dioxide from the tissues to the lungs.
It needed a "green lung" to breathe, regardless of cost.
During the sixth China International Import Expo held in Shanghai in early November, German biopharmaceutical company Boehringer Ingelheim announced a strategic cooperation agreement with Chinese high-tech company ChromX Health, to jointly push forward research on interstitial lung diseases, and search for innovative early diagnosis and intervention solutions.
Interstitial lung diseases are a large group of disorders that can cause progressive scarring of lung tissue if not treated on time and effectively, resulting in difficulty breathing or even death.
The therapy can significantly reduce the rate of acute attacks and improve lung function and asthma control rapidly and durably.
The company said that the medicine showed good results in Phase-III clinical research, and was found to improve lung function and quality of life for COPD patients.
Li said that "riding is a whole body exercise, which is friendly to the knees and other vulnerable parts, while also exercising the heart and lung function and improving the overall body functions.